Dunad Therapeutics is pleased to share that our CEO and President, Pearl S. Huang , has been elected to the 2026 Class of the American Institute for Medical and Biological Engineering College of Fellows. The AIMBE College of Fellows brings together leaders across academia, industry, and medicine whose work is shaping the future of biomedical engineering. Dr. Huang’s election reflects a career dedicated to advancing innovative approaches in biotechnology, as well as a stron

Dunad Therapeutics  is excited to welcome  Stephen Huhn, MD , as our Chief Medical Officer.   Dr. Huhn’s experience leading early translational, clinical, and regulatory strategy for complex neurodegenerative disorders marks a significant step forward as Dunad moves our development candidate into IND-enabling studies and prepares to transition into a clinical stage company.  Dr. Huhn has led early and mid-stage clinical development covering a wide range of neuroscience indic

Dunad Therapeutics is pleased to announce the formal nomination of Development Candidate, DUN’040 for the treatment of both sporadic and familial ALS . DUN’040 is a first-in-class covalent, brain-penetrant small molecule inhibitor of the lipid kinase PIKfyve that mitigates the TDP-43 proteinopathy found in 97% of all ALS patients. Modulating TDP-43 by PIKfyve inhibition represents a disease modifying therapy and a critical proximal disease target in ALS, and potentially othe

Dunad Therapeutics is proud to announce a speaker presentation by our Associate Director, Dr. Antony Burton, at the 2 nd Proteomics-based Drug Discovery Summit in Boston, MA February 2-4. You can get a preview of his talk, entitled, “Chemoproteomics discovery of a CNS-penetrant covalent inhibitor of PIKfyve” , on Biorxiv here: https://www.biorxiv.org/content/10.64898/2026.01.26.701341v1